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SUMMARY
PATERSON, ALAN R. P., NAIK, SHAMBU R. & CAss, CAROL E. (1977) Inhibition
of uridine uptake in HeLa cells by nitrobenzylthioinosine and related compounds.
Mol. Pharmacol., 13, 1014-1023.
Rates of uridine uptake by logarithmically proliferating monolayer cultures of HeLa
cells at 20#{176}were constant for intervals of several minutes, and rate saturability was
evident. Nitrobenzylthioinosine (NBMPR), a potent inhibitor of nucleoside transport,
abolished saturable uptake of uridine, revealing a nonsaturable component of uptake
that apparently was due to simple diffusion. Under conditions of the uptake assay, the
principal metabolite of uridine was UTP. NBMPR had no effect on uridine kinase in
HeLa cell extracts, or on the relative proportions of uridine anabolites in intact cells.
These results indicate that NBMPR inhibited mediated passage of uridine into the cell.
The inhibition of uridine transport by NBMPR was characterized by unchanged Vmax
values, with increases in apparent K, values, whether the inhibitor and permeant were
added simultaneously in the uptake assay or the cells had previously been treated with
inhibitor. To assess the structural requirements for inhibitory activity, compounds
related structurally to NBMPR were tested for their ability to inhibit uridine uptake; of
these, the most effective were the 2’-deoxyribosyl and arabinosyl analogues of NBMPR
and the S6-nitrobenzyl derivatives of 6-thioguanosine, 2’-deoxy-6-thioguanosine, and 6-
selenoguanosine.
INTRODUCTION
The transport of uridine across the
plasma membrane of human erythrocytes
has been clearly established as a facili-
tated diffusion process; these cells do not
metabolize uridine (1, 2). In cells that me-
tabolize nucleosides, the transport of such
permeants has been studied mainly
through initial rate kinetics of uptake.’
Rate saturability, competition between
permeants, and the existence of specific
inhibitors have been interpreted to mean
that a rate-limiting step in the uptake
process is mediated. It is frequently as-
sumed that this step is transport (3, 4).
Although difficult to demonstrate rigor-
ously, it has been argued that transport is
rate-limiting in uridine uptake by cells
that metabolize this nucleoside (5-8).
However, the functional independence of
transport and subsequent metabolic steps
This work was supported by the National Cancer
Institute of Canada and the Medical Research Coun-
cil of Canada.
Transport refers to the mediated passage of per-
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meant across the plasma membrane: uptake of per-
meant, which refers to intracellular accumulation of
permeant and its metabolites, includes a transport
step.
1014
INHIBITION OF URIDINE UPTAKE 1015
in the uptake of uridine or other nucleo-
sides has not been established.
A variety of substances chemically unre-
lated to nucleosides inhibit the transport
of uridine; for example, Persantine (5), cy-
tochalasin B (9), and phloretin (10) are
inhibitory, changing the kinetics of uptake
(Vmax unaltered, Km increased), possibly
by direct interaction with the transport
elements of the membrane or by changing
their milieu. Various S6 derivatives of 6-
thio -9- /3-D-ribofuranosylpurine (e.g.,
NBMPR2) are potent inhibitors of nucleo-
side transport. These compounds are evi-
dently specific toward nucleoside permea-
tion because (a) they block cellular uptake
of nucleosides, but not of bases, glucose, or
amino acids (11), and (b) their aglycones
are much less inhibitory (12, 13).
In the present study, a rapid sampling
procedure was used to examine the kinet-
ics of uridine uptake and metabolism in
HeLa cell monolayers, and inhibition of
uridine uptake by NBMPR was compared
with that by a number of structurally re-
lated compounds.
METHODS
HeLa cell monolayers were maintained
in MEM-M (Eagle’s minimal essential me-
dium with 10% calf serum) with subcul-
ture at weekly intervals. Trypsinized mono-
layer cultures provided inocula for sus-
pension cultures in MEM-S [MEM without
calcium salts and supplemented with 5%
calf serum, penicillin (100 units/ml), strep-
tomycin (100 g/ml), and 2 m HEPES
buffer, pH 7.4]. Suspension cultures were
initiated in spinner flasks and, after ex-
pansion into 2- or 5-liter round-bottomed
flasks, were kept under continuous agita-
tion with a Vibro-Mixer (model El, Che-
mapec, Hoboken, N. J.) and maintained in
exponential growth by dilution. Vibro-
Mixer cultures, being single-cell suspen-
sions, were used to prepare replicate mono-
layer cultures. Cell culture materials were
purchased from Grand Island Biological
2 The abbreviations used are: NBMPR, nitroben-
zylthioinosine (6-[(4-nitrobenzyl)thio]-9-f3-1-ribofu-
ranosylpurine; MEM, Eagle’s minimal essential me-
dium; HEPES, N-2-hydroxyethylpiperazine-N’-2-
ethanesulfonic acid.
Company. Stock cultures, tested at regu-
lar intervals by Dr. Janet Robertson, De-
partment of Medical Bacteriology, Univer-
sity of Alberta, were mycoplasma-free.
Uptake experiments employed replicate
monolayer cultures, prepared in 2-ounce
prescription bottles (Brockway Glass Com-
pany, Brockway, Pa.). Bottles were “condi-
tioned” for 24 hr at 37#{176}with MEM-M
(which was then discarded) and then inoc-
ulated with l0 cells in 4.0 ml of MEM-A
(equal volumes of MEM-M and MEM-S).
Plating efficiencies were 50-60%, and,
after a 4-hr lag, cells proliferated exponen-
tially with doubling times of about 20 hr.
The replicate cultures were used 24 hr
after inoculation, at which time prolifera-
tion was exponential.
Uridine uptake by the replicate mono-
layer cultures was assayed at 20#{176}as fol-
lows; exceptions to this procedure are
noted. Each assay was performed in tripli-
cate, and each bottle was passed individ-
ually through the following sequence. (a)
Growth medium was aspirated, the bottle
was then placed horizontally with the cell
sheet uppermost, and 4.0 ml of transport
medium (MEM-T3) containing [5-3H]uri-
dine were added to the bottle. (b) To
initiate the uptake interval, the cell sheet
was immersed by rapidly rotating the bot-
tle 180#{176}around its long axis. (c) Aspiration
of the permeant-containing medium was
started 5 sec before the interval ended. (d)
To end the uptake interval, the cell sheet
was flooded with 60 ml of ice-cold 0.154 M
NaCl, which was removed rapidly by aspi-
ration after 15 sec. The bottles were thor-
oughly drained by a brief centrifugation in
the inverted position. Cell sheets were dis-
solved in 1.5 ml of NCS tissue solubilizer
(Amersham/Searle), and the digests were
assayed for radioactivity by liquid scintil-
lation counting, using Bray’s scintillation
fluid (14). Four to eight cultures from each
set of replicates were treated with trypsin
for determination of cell number with an
electronic particle counter. Permeant up-
take during assay intervals of 0 sec was
estimated by flooding cell sheets with 60
MEM-T consisted of MEM without serum and
bicarbonate, but containing 20 mai HEPES (pH 7.4
at 20#{176}).
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ml of ice-cold 0.154 M NaCl containing 0.35
ml of permeant-containing MEM-T [the
amount remaining after step (c) above].
Permeant specific activities were deter-
mined in the presence of blank NCS cell
digests.
Time courses of uridine uptake were lin-
ear over extended intervals at 37#{176}and 20#{176},
as demonstrated in Figs. 1 and 3, and ex-
trapolated through zero time. Except as
noted, uridine uptake rates were deter-
mined as the difference between the cellu-
lar content of uridine after 60-sec and 0-sec
exposures to medium containing [5-
3H]uridine. Rates of nucleoside uptake
(picomoles per 106 cells per minute) were
found to be independent of cell number in
the range employed, 0.8-1.5 x 106 cells/
monolayer.
To examine uridine metabolism, mono-
layer cultures were exposed to MEM-T
containing 4 ji [5-3H]uridine for intervals
that were initiated and terminated as in
the uptake assay; cultures were processed
individually in sets of five in the following
manner. After removal of the stopping so-
lution, the first bottle was immediately
placed on ice, and at once the cell sheet
was extracted for 2 mm with 1.5 ml of cold
0.5 M perchioric acid; this extract was
passed in succession over four additional
cell sheets, each exposed to [5-3H]uridine
in the same manner as the first. The ex-
tract, then representing five cultures, was
neutralized on ice with KOH, using brom-
cresol purple as an internal indicator.
Such extracts were freeze-dried and recon-
stituted in 300 l of 1.0 mri phosphate
buffer (pH 6.5), and 30-1.d portions, along
with appropriate carriers (50 nmoles
each), were chromatographed on thin lay-
ers of cellulose or polyethylenimine cellu-
lose. After development, carrier areas were
scraped onto filter paper and combusted in
a Packard model 305 Sample Oxidizer for
assay of radioactivity by liquid scintilla-
tion counting. Chromatographic system I
employed polyethylenimine cellulose
sheets (MN 300, Machery-Nagel and Com-
pany, Brinkmann Instruments) prepared
by washing with 4 M sodium formate
buffer (pH 3.4) for 18 hr, followed by two 1-
hr immersions in 50% methanol. In system
I, chromatograms were developed with 0.5
M, 2.0 M, and 4.0 M sodium formate buffers
(pH 3.4) employed in succession, without
drying between transfers; transfers were
made when fronts moved 2.5 and 10 cm
above the origins, and development in 4.0
M sodium formate was stopped when the
front had moved 17 cm. Chromatographic
system II employed Eastman 6064 cellu-
lose thin-layer sheets developed in ethyl
acetate-isopropyl alcohol-water (65:22.5:
12.5, v/v/v).
Cell extracts, prepared in the following
way, were assayed for uridine kinase ac-
tivity (15). Cell suspensions, about l0
washed HeLa cells in 1.2 ml of 0.15 M KC1
containing 3 mi mercaptoethanol and 10
mM Tris-HC1 (pH 8.5), were disrupted
with 20-kc ultrasound and centrifuged at
10,000 x g for 10 mm at 4#{176};the superna-
tants were assayed for protein content
(16). Kinase assay mixtures contained 9
mM ATP, 9 m MgCl2, 7.5 m 3-phospho-
glycerate, 50 m Tris-HC1 (pH 8.5), 100 il
of cell extract (approximately 600 jg of
protein), and 10 iM [2-’4C]uridine in a to-
tal volume of 400 1il. Assay mixtures were
incubated at 37#{176},and at 5-mm intervals 20-
pi portions were applied to 2.5-cm2 squares
of DEAE paper, which, after washing with
10 m sodium phosphate (pH 6.8), were
combusted for assay of ‘4C.
NBMPR and the S6-(4-nitrobenzyl) de-
rivatives of 6-mercaptopurine, 6-thioguan-
in 6-thioguanosine, and the a and /3 an-
omers of 2’ -deoxy-6-thioguanosine (pro-
vided by Dr. G. A. LePage) were prepared
by established methods (17). 4-[(4-Nitro-
benzyl)thio]uridine was prepared by the
method of Sato and Kanaoka (18). [2-
‘4C]Uridine and [5-3H]uridine were com-
mercial products; radiochemical purities,
determined by paper chromatography, ex-
ceeded 90%.
RESULTS AND DISCUSSION
The effect of relatively high concentra-
tions of NBMPR on uridine uptake by
HeLa cells is shown in Fig. 1. When
NBMPR was present during the uptake
assay, almost complete inhibition of un-
dine uptake resulted. When NBMPR-




































INHIBITION OF URIDINE UPTAKE 1017
TIME (mm)
FIG. 1. NBMPR inhibition of uridine uptake by
HeLa cells
The effect of NBMPR on uridine uptake by repli-
cate monolayer cultures was measured with
NBMPR and uridine added together (U, A) or after
NBMPR treatment (Lx). In the latter procedure,
monolayers were individually incubated at 37C for 6
mm in MEM-M containing 56 .cM NBMPR and
washed in NBMPR-free medium. In the uptake as-
say, monolayers were incubated at 37#{176}in MEM-M
containing 0.7 cM [2-’4C]uridine with (A) or without
(#{149},E) 56 tM NBMPR, or with the latter added
(arrow) at 6 mm (U).
uridine uptake in NBMPR-free medium,
substantial inhibition of this process re-
mained. This persistent inhibitory effect
was further examined in the experiment of
Fig. 2, which showed that in cells treated
with NBMPR and then washed, the Vmax
of uridine uptake was unchanged but the
half-saturation constant (K,,,) for this proc-
ess was increased. Evidently NBMPR re-
mained associated with cells during wash-
ing and the relatively long intervals of the
unidine uptake assays. These results are
consistent with reports of the tight, but
reversible, binding of NBMPR to erythro-
cytes (19, 20) and HeLa cells (21).
The kinetics of unidine uptake at 20#{176}was
studied with the rapid sampling technique
described in METHODS, which provided the
time courses of Fig. 3. Because such time
courses were linear, cellular uptake of un-
dine during the first 60 sec measured up-
take rate. The data of Fig. 4 show that
NBMPR is a potent inhibitor of unidine
FIG. 2. Inhibition of uridine uptake in HeLa cell
monolayers by prior treatment u’ith NBMPR
Cultures from a replicate set were individually
incubated at 37#{176}for 6 mm in MEM-M with (0 or
without (#{149}62 j.cM NBMPR and, after washing with
MEM-M, were assayed for [2-’4C]uridine uptake at
37#{176},as in Fig. 1; uptake rates were calculated from
differences between uptake after 6 and 18 mm of
incubation. Km values for control and NBMPR-
treated cells were 3.9 and 10.5 M, respectively, and
the common Vmax value was 95 pmoles/106 cells/mm.
FIG. 3. Constant rate of uridine uptake by HeLa
cell monolayers
Replicate cultures were incubated at 20#{176}in MEM-
T containing 3 or 30 j.M [5-3H]uridine, and the cellu-
lar content of [5-’H]uridine was determined.
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FIG. 5. Apparent diffusion component of uridine uptake
Rates of uptake 15-3H]uridine at 20#{176}were determined in the absence (0) and presence (Lx) of 5 M NBMPR.
A. Uridine uptake rates in the presence of 5 M NBMPR were attributed to simple diffusion and subtracted
from control rates to determine mediated uptake (0). B. Reciprocals of mediated uptake data (0) from A:
Vmax, 39 pmoles/106 cells/mm; Km, 2.0 LM.
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uptake. When cells were incubated in me-
dium containing 3 pM unidine and graded
concentrations of NBMPR, unidine uptake
rates were reduced by 50% when the
NBMPR concentration (IC50) was 0.05 jIM;
in four experiments, including that of Fig.
4, IC values ranged between 0.05 and
0.08 p.M (mean, 0.06 p.M). Figure 4 also
demonstrates that prior treatment with














toward unidine uptake than the same con-
centration of NBMPR added together with
[5-3H]unidine in the unidine uptake assay.
The experiments of Fig. 5 showed that
the mediated uptake of uridine by HeLa
cells was abolished by the presence of 5 p.M
NBMPR. The rate of unidine uptake was
directly proportional to concentration in
the medium when the latter contained 5
p.M NBMPR, suggesting that this compo-
NBMPR (SM)
to to
FIG. 4. NBMPR inhibition of uridine uptake by HeLa cell monolayers at 20#{176}
The effects of graded concentrations of NBMPR on rates of uridine uptake were determined when 3 M
[5-3H]uridine was added to the replicate cultures together with NBMPR (0) or following treatment with
NBMPR (0). In the latter procedure, cell sheets were exposed for 1.0 mm to MEM-A containing NBMPR
at the indicated concentrations, washed for 30 sec with 4.0 ml of MEM-A, and immediately assayed for
uridine uptake. All cultures were processed individually through these procedures. Uptake rates were cor-





FIG. 6. Effect of NBMPR on uridine uptake kinetics
Rates of [5-3H]uridine uptake by replicate monolayer cultures at 20#{176}were measured in the absence (0)
and presence (0) of 0.05 p.M NBMPR. Rates were corrected for uridine uptake by diffusion, as in Fig. 5.
Kinetic constants in the absence of NBMPR: Vmax, 67 pmoles/106 cells/mm; Km, 4.2 p.M.
TABLE 1 TABLE 2
Failure of NBMPR to inhibit uridine kinase activity Time course of uridine metabolite formation by HeLa
cell monolayers
10 20
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“Assayed by measurement of uridine phospho-
rylation.
nent of unidine uptake was due to simple
diffusion. It is also possible that this com-
ponent of unidine uptake could be due to a
NBMPR-insensitive nucleoside uptake
process with a very low affinity for un-
dine. When gross uptake rates were cor-
rected for the apparent diffusion compo-
nent (Fig. 5A), the satunability of unidine
uptake rates was evident (Fig. 5B). The
following values for rates of apparent un-
dine diffusion at 20#{176}were determined in
separate experiments: 0.8 (Fig. 5), 1.1, and
0.9 pmoles/l06 cells/mm/unit of unidine
concentration (1.0 p.M); the mean (0.9) was
applied where indicated as a correction to
gross rates of unidine uptake.
The influence of concentration on un-
Replicate monolayer cultures were exposed at 200
to MEM-T containing 4 /.LM [5-3H]uridine; intervals
of exposure were ended exactly as in the determina-
tion of uptake rate (Fig. 3). The cold saline stopping
solution was removed after 15 sec, monolayers were
extracted immediately with cold perchloric acid, and
the extracts were analyzed by chromatography. 3H
accompanying the chromatographic carriers listed
accounted for more than 95% of that applied to the
chromatograms. Radioactivity present in cytidine
and its phosphates was insignificant.
NBMPR Incubation Uridine UMP UDP UTP
interval
sec cpm/30 1.d extract
- 10 1,046 104 119 2,019
30 648 312 389 5,459
60 896 486 717 9,658
90 783 723 993 13,035
+ 10 687 36 14 274
60 695 83 63 913
dine uptake rates in the presence and ab-
sence of 0.05 p.M NBMPR was evaluated in
the experiments of Fig. 6; Vmax for unidine
uptake was essentially unchanged in the
inhibited cultures, but the apparent Km
value was increased. Similar results (inhi-
bition without change in Vmax) were ob-
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TABLE 3
Inhibition of uridine uptake
Rates of uptake of [5-3H]uridine (3 or 4 p.M) by HeLa cell monolayers were measured at 20#{176}in the absence
and presence of at least three concentrations of each test compound. Control uptake rates of 3 and 4 p.M
uridine were 19.7 ± 3.6 and 32.0 ± 3.8 pmoles/min/108 cells (mean ± SD for 11 and six determinations,
respectively). IC,0 values [concentrations of test compound which reduced uridine uptake rates to 50% of the
uninhibited (control) rate] were estimated from plots of inhibition percentage against log inhibitor concen-
tration; concentration ranges of the test compound included the IC,0 value (Table 3A). Partially inhibitory
compounds (Table 3B) are listed together with the highest concentration tested and the inhibition percent-
age obtained at that concentration. Compounds with little or no effect on uridine uptake at the concentra-
tion indicated are listed in Table 3C. Compounds were obtained from the following sources: A, commercial;
B, this laboratory; C, M. J. Robins, University of Alberta; D, L. B. Townsend, University of Utah; E, J. P.
Miller and R. A. Long, ICN Nucleic Acid Research Institute, Irvine, CA; F, Drug Research and Develop-
ment, National Cancer Institute, Bethesda, Md.; G, K. C. Tsou, University of Pennsylvania; H, H. J.
Schaeffer, Medical College of Virginia.
A. Inhibitory compounds
No. Test compound Source IC,0
p.M
914 2-AnlTho-6-[(4-nitrobenzyl)thio]-9-f3-n-2’-deoxyribofuranosylpurine B 0.03
947 6-[(4-Nitrobenzyl)thio]-9-/3-D-arabinofuranosylpurine E 0.04
554 6-[(4-Nitrobenzyl)thio]-9-/3-n-ribofuranosylpurmne B 0.06
844 6-[(4-Nitrobenzyl)thio]-9-j3-n-2’-deoxyribofuranosylpurine C 0.10
218 2-Amino-6-[(4-nitrobenzyl)thio]-9-f3-n-ribofuranosylpurine B 0.1
852 2-Amino-6-[(4-nitrobenzyl)seleno]-9-3-r-ribofuranosylpurine D 0.1
861 6-[(4-Nitrobenzyl)thio]-9-f3-D-2’-O-methylribofuranosylpurine C 0.1
120 6-(Benzylthio)-9-f3-n-rmbofuranosylpurine F 0.25
938 6-(Benzylthio)-9-f3-r-arabinofuranosylpurine E 0.5
555 2-Amino-6-[(2-hydroxy-5-nitrobenzyl)thio]-9-f3-D-ribofuranosylpurine B 1.0
915 2-Amino-6-[(4-nitrobenzyl)thio]-9-a-n-2’-deoxyribofuranosylpurine B 1.0
862 6-[(4-Nitrobenzyl)thio]-9-f3-D-3’-O-methylribofuranosylpurine C 2.4
937 6-N-(3-Methylbut-2-enylamino)-9-f3-n-arabinofuranosylpurine E 4.0
925 6-[(4-Nitrophenacyl)thio]-9-f3-i-ribofuranosylpurine B 4.5
946 6-(Allylthio)-9-/3-r-arabinofuranosylpurine E 5
926 6-(Benzylthio)-9-/3-n-ribofuranosylpurine cyclic 3’ ,5’-monophosphate E 10
944 6-(Ethylthio)-9-/3-r-arabinofuranosylpurine E 10
943 6-(Thiocyanato)-9-/3-r-arabinofuranosylpurine E 40
867 4-[(4-Nitrobenzyl)thio]-1-f3-D-ribofuranosylpyrimid-2-one B 40
942 6-(Methylthio)-9-f3-n-arabinofuranosylpurine E 70
served with cells that had received prior
treatment with NBMPR. However, anal-
ogy with enzyme kinetics, which would
suggest competition between permeant
and inhibitor, is evidently not valid, be-
cause inhibition of nucleoside uptake (a)
by a variety of substances structurally
unrelated to nucleosides on (b) by prior
treatment of cells with p-chloromercuni-
benzoate (22) on with NBMPR (as reported
here) is also characterized by unchanged
Vm, values.
Since the principal fate of unidine in
HeLa cells is conversion to uridine phos-
phates (see below), it was possible that
NBMPR inhibition of unidine uptake re-
sulted from inhibition of unidine phospho-
rylation. The data of Table 1 show that
NBMPR did not inhibit unidine kinase ac-
tivity in cell extracts. Table 2 indicates
that, while NBMPR significantly reduced
the incorporation of external unidine into
cellular unidine nucleotides under condi-
tions of the uptake assay, the relative dis-
tribution of [5-3H]unidine anabolites
among UMP, UDP, and UTP was the
same in the presence and absence of
NBMPR. Thus NBMPR did not appear to
inhibit the intracellular anabolism of urn-
dine, and inhibition of uptake at the level
of permeation was indicated. Although
most of the radioactivity recovered was in
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TABLE 3-Continued
B. Partially inhibitory compounds
No. Test compound Source Concen - Inhibi-
tration tion
p.M %
109 6-(Methylthio)-9-3-r-ribofuranosylpurine A 10 29
940 6-(3-Pyridylmethylthio)-9-f3-n-arabinofuranosylpurine E 10 45
928 6-(Methylthio)-9-3-r-ribofuranosylpurine cyclic 3’ ,5’-monophosphate E 10 31
948 6-Thio-9-f3-n-arabinofuranosylpurine E 100 25
945 6-Sulfenamide-9-f3-D-arabinofuranosylpurine E 100 17
939 6-Hydrazino-9-/3-n-arabinofuranosylpurine E 100 31
941 6-(f3-Hydroxyethylamino)-9-f3-r-arabinofuranosylpurine E 100 35
Colchicine A 200 38
C. Compounds with little or no effect
No. Test compound Source Concen-
tration
p.M
924 6-[(4-Nitrobenzyl)thio]purine B 1
923 2-Amino-6-[(4-nitrobenzyl)thio]purine B 1
920 2-Amino-6-thio-9-f3-r-2’-deoxyribofuranosylpurine A 1
863 1-N6-Etheno-9-f3-r-ribofuranosylpurine G 1
922 6-Amino-9-f3-r-2’-O-methanesulfonylribofuranosylpurine C 10
921 2-Amino-9-f3-n-2’,3’-anhydroribofuranosylpurine C 10
866 1-N6-Etheno-2-aza-9-f3-1-ribofuranosyladenine G 10
927 6-(Ethylthio)-9-/3-D-ribofuranosylpurine cyclic 3’ ,5’-monophosphate E 10
929 6-Thio-9-f3-r-ribofuranosylpurine cyclic 3’ ,5’-monophosphate E 10
931 NeEthyl9f3D-ribofuranosyladenmne cyclic 3’ ,5’-monophosphate E 10
933 N6-Hydroxy-9-f3-n-ribofuranosyladenine cyclic 3’ ,5’-monophosphate E 10
934 cyclic 3’ ,5’-monophosphate E 10
935 N6-Benzyl-9-f3-c.-ribofuranosyladenine cyclic 3’ ,5’-monophosphate E 10
930 NeMethyl9f3D-ribofuranosyladenmne cyclic 3’ ,5’-monophosphate E 10
2-Amino-6-thiopurine A 10
Showdomycin A 10
918 2’-Deoxycoformycin F 187
868 9-erythro-(2-Hydroxy-3-nonyl)adenine hydrochloride H 187
UTP, the principal metabolite of unidine,
free uridine was present in perchloric acid
extracts of cells incubated in the presence
and absence of NBMPR (Table 2); similar
results were obtained when the experi-
ment of Table 2 was repeated, except that
a somewhat greater proportion of radioac-
tivity was present in extracts as free urn-
dine.
The unidine uptake mechanism of HeLa
cells appeared to be specific for unidine,
since in the presence of 10 p.M thymidine
[for which the Km for uptake by these cells
is about 0.5 p.M (23)], the kinetics of un-
dine uptake was unaffected and essen-
tially the same as that of the controls in
Fig. 6. In similar experiments, the pres-
ence of unidine had little effect on rates of
cellular uptake of thymidine (23), adeno-
sine (24), on guanosine.4
Human erythrocytes transport unidine
by a facilitiated diffusion mechanism,
which functions independently of unidine
metabolism. NBMPR inhibits this trans-
port process by binding with high affinity
to specific receptor sites in the erythrocyte
plasma membrane (19, 20). In HeLa cells,
the lack of a NBMPR effect on unidine me-
tabolism, together with the capacity of
NBMPR to eliminate the saturable uptake
of uridine (as shown with enythnocytes),
suggests that the inhibition of unidine up-
take by NBMPR occurs by interference
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with the transport portion of the uptake
process; a similar conclusion has been re-
ported for NBMPR inhibition of thymidine
uptake in HeLa cells (23).
Table 3 summarizes experiments which
tested compounds related to NBMPR for
their ability to inhibit unidine uptake by
HeLa cells. These results demonstrate
that (a) the pentosyl and 6-(4-nitroben-
zyl)thio groups contribute importantly to
the inhibitory activity, (b) the 2’-hy-
droxyl group of NBMPR does not appear to
be involved in the inhibitor-transporter in-
teraction and an 0-methyl group is accom-
modated at this position, (c) the presence
of an amino group at the punine 2-position
does not affect the inhibitor-transporter
interaction, (d) 3’-O substituents are less
well tolerated than those at the 2’-O posi-
tion, (e) NBMPR and its seleno homologue
have comparable inhibitory activity in this
system, (f) of the two possible configura-
tions for the N9-glycosidic bond, the /3 an-
omen is preferred, and (g) the cyclic 3’ ,5’-
monophosphate derivatives are not ac-
cepted by the inhibitor receptor site as
readily as the corresponding free nucleo-
sides. 4-(Nitrobenzylthio)uridine (com-
pound 867) was far less inhibitory than its
purine homologue, NBMPR, suggesting
that the inhibitor receptor site is punine-
specific.
NBMPR did not inhibit the uptake of
uracil or the following other low molecular
weight compounds, indicating a specific
inhibitory effect against uptake of nucleo-
sides. Uptake experiments were per-
formed as described for unidine, in the
presence and absence of 25 p.M NBMPR,
using the following permeants (data not
shown): [5-3H]uracil (1, 5, and 25 p.M), 1-
[U-’4C]glucose (1, 5, and 10 mM), L-[4,5-
3H]leucine (0.05, 0.5, and 5 mM), and a
mixture of 15 L-[G-3H]amino acids5 (0.1, 1,
and 10 p.M).
In a previously reported study, various
nucleoside derivatives, some related to
The mixture consisted of equal concentrations of
alanine, arginine, aspartic acid, glutamic acid, gly-
cine, histidine, isoleucine, leucine, lysine, phenylal-
anine, proline, serine, threonine, tyrosine, and va-
line.
NBMPR, were compared for their ability
to inhibit a tnanspbrt-dependent aspect of
nucleoside metabolism in human erythro-
cytes (25). 6-Benzylthio, 6-benzylamino,
and 6-benzyloxy derivatives of 9-/3-1-ribo-
furanosylpurine displayed similar inhibi-
tory potency, and the hydrophobicity of the
6-position substituents appeared to con-
tribute importantly to inhibitory activity,
suggesting strong interaction with a hy-
drophobic region of the inhibitor receptor
site. A number of compounds are potent
inhibitors in both the erythrocyte and
HeLa cell assay systems, and while there
may be differences between the two cell
systems in the binding affinities of one
inhibitor relative to another, there does
not appear to be distinct cell-inhibitor
specificity.
Kinetic studies, including those re-
ported here, suggest that human erythno-
cytes (1, 2, 26) and HeLa cells (23, 24)
possess nucleoside uptake mechanisms
which differ in important respects. Nucleo-
sides are transported in enythrocytes by a
mechanism6 with low specificity toward
nucleoside permeants and low affinity for
the latter relative to other cells. By con-
trast, in HeLa cells, four mechanisms of
nucleoside uptake7 are distinguishable by
kinetic criteria and by changes in activity
during the replication cycle.8 It is not
known whether these mechanisms are in-
dependent or whether the specificities evi-
dent are imparted at the levels of transport
on metabolism in the uptake process. De-
spite these functional dissimilarities, the
structure-activity data reported here for
NBMPR inhibition of nucleoside trans-
port, when compared with data reported
elsewhere for erythrocytes (20, 25, 26), in-
 A criterion for permeant specificity in the eryth-
rocyte system was the acceleration of exchange dif-
fusion of [‘4C]uridine induced by structurally re-
lated test permeants; such an assay would not iden-
tify additional mechanisms with overlapping speci-
ficities.
The following uptake mechanisms are distin-
guishable: (a) uridine (this work), (b) thymidine and
certain thymidine analogues (23), (c) adenosine (24),
and (d) inosine and guanosine.4
$ C. E. Cass and A. R. P. Paterson, unpublished
observations.
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dicate a strong resemblance between the
NBMPR receptor sites of erythnocytes and
HeLa cells.
Note added in proof Eilam and Cabant-
chik (27, 28) have reported recently that
nitrobenzylthioinosine is a very potent in-
hibitor of unidine uptake by MCT cells, a
cultured line of hamster cells, and have
suggested that binding of the inhibitor
may induce a conformational change in
the transporter which reduces affinity of
the latter for unidine.
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